Navigation Links
LCA-Vision Conducts 2008 Annual Stockholder Meeting
Date:5/14/2008

hat are subject to risks and uncertainties. These forward-looking statements in this release are based on information available to us as of the date hereof. Actual results could differ materially from those stated or implied in our forward-looking statements due to risks and uncertainties associated with our business, including, without limitation, those concerning economic, political and sociological conditions, which can affect our procedure volume and revenue; the acceptance rate of new technology, and our ability to successfully implement new technology on a national basis; market acceptance of our services; the successful execution of marketing strategies to cost effectively drive patients to our vision centers, which recent results would indicate are no longer as effective as they have been in prior periods; competition in the laser vision correction industry; an inability to attract new patients; the possibility of long-term side effects and adverse publicity regarding laser vision correction; operational and management instability; legal or regulatory action against us or others in the laser vision correction industry; our ability to successfully open new vision centers, including our ability to reach profitability targets for new vision centers within a specified time period; the relatively high fixed cost structure of our business; the continued availability of non-recourse third-party financing for our patients on terms similar to what we have paid historically; and the future value of revenues financed by us and our ability to collect on such financings which will depend on a number of factors, including the consumer credit environment and our ability to manage credit risk related to consumer debt, bankruptcies and other credit trends. In addition, the FDA's advisory board on ophthalmic devises is currently reviewing concerns about post-Lasik quality of life matters and the advisory board may propose a major new study on Lasik outcomes. The outcome of th
'/>"/>
SOURCE LCA-Vision Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. LCA-Vision to Present at the Bank of America 2008 Health Care Conference
2. LCA-Vision Announces the Opening of its 76th LasikPlus(R) Vision Center in Woodbridge, New Jersey
3. LCA-Vision Announces the Opening of its 75th LasikPlus(R) Vision Center in Tulsa, Oklahoma
4. LCA-Vision Announces the Opening of its 74th LasikPlus Vision Center in Des Moines, Iowa
5. LCA-Vision Announces Quarterly Dividend Payment
6. LCA-Vision Reports Fourth Quarter and Full-Year 2007 Financial Results
7. LCA-Vision Announces Upcoming Investment Community Events
8. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against LCA-Vision Inc.
9. Hospital Clínic conducts the first kidney extraction through the vagina in Europe
10. HeartWare to Present at Seventh Annual JMP Securities Research Conference
11. Mindray to Present at the Oppenheimer 2nd Annual China Dragon Call Conference and 2008 Citi Investment Research Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... chronic kidney disease patients may be a strong indicator ... in the Journal of the American Society of ... Hopkins Bloomberg School of Public Health assert that coronary ... atherosclerosis in predicting the risk of heart disease among ... all patients with chronic kidney disease (CKD) die from ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pulmonary ... with an Education Forum for PH patients and ... Who:    The Pulmonary Hypertension Association – the ... find ways to prevent and cure pulmonary hypertension ... affects the functioning of the heart and can ...
(Date:8/21/2014)... Researchers have pinpointed the environmental source of fungal infections ... for decades. It literally grows on trees. , The ... 13-year-old girl, who spent the summer gathering soil and ... by infections of the fungus named Cryptococcus gattii ... which encompasses a number of species including C. ...
(Date:8/21/2014)... -- Black mothers are less likely than white moms ... why: Hospitals in neighborhoods with many black residents do ... more white residents, a U.S. government study finds. ... in medical centers where the black population is higher ... Control and Prevention reported Thursday. These practices include ...
(Date:8/21/2014)... THURSDAY, Aug. 21, 2014 (HealthDay News) -- Among seniors, ... suggests. The study involved more than 2,500 people, aged ... the study and again two, six and eight years later. ... in the person,s risk of death during the study period, ... and effect, researchers led by Sharon Christ of Purdue University ...
Breaking Medicine News(10 mins):Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 3Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2
... Interim Results from National Chronic Disease ... ... participants in the Diabetes Ten City Challenge (DTCC) improved across,all ... of,the program, the American Pharmacists Association (APhA) Foundation,announced today., ...
... CHAPEL HILL, N.C., March 12 R&D structure ... is,essential to pharmaceutical companies. In a competitive market ... process increases -- the need to have an,optimized ... Discover the best-suited organizational structure that promotes rapid,growth, ...
... Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... Annual Lehman Brothers Global Healthcare Conference will ... visiting the Investors section of the,Company,s website, ... ), The presentation will include ...
... XTNT ) today announced that Gregory D. Casciaro, ... Company,s 28th Annual,Health Care Conference on Tuesday, March 18, ... at the Boston Marriot Copley Place in Boston, MA., ... device company focused on developing and,commercializing innovative customizable drug ...
... its ongoing effort to,give consumers information to improve ... four area hospitals have been,selected as Blue Distinction ... Distinction(R) is a nationwide program created to give ... and to work with their,health care providers to ...
... 12 Accuray,Incorporated (Nasdaq: ARAY ), a global ... company received the 2008 North American Medical,Devices Product of ... Sullivan, for its CyberKnife(R) Robotic Radiosurgery System., The ... is presented each,year to the company that has demonstrated ...
Cached Medicine News:Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 2Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 3Health News:Diabetes Ten City Challenge Collaborative Model Shows Improved Patient Health Across Key Clinical Indicators 4Health News:R&D Quality Excellence: Proven Tactics Optimize the R&D Quality Organizations of Pharmaceutical and Biotech Industries 2Health News:Eleventh Annual Lehman Brothers Global Healthcare Conference to Webcast Millennium Presentation 2Health News:Independence Blue Cross Announces Blue Distinction Centers for Complex and Rare Cancers(SM) in Philadelphia 2Health News:Independence Blue Cross Announces Blue Distinction Centers for Complex and Rare Cancers(SM) in Philadelphia 3Health News:Accuray's CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan 2Health News:Accuray's CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan 3
(Date:8/21/2014)... , Aug. 21, 2014  AliveCor, Inc. ... Drug Administration (FDA) has granted the company ... fibrillation (AFib), the most common form of ... instantly detects if patients are experiencing AFib ... the mobile phone based AliveCor® Heart Monitor, ...
(Date:8/21/2014)... , Aug. 21, 2014   Royal Philips ... today announced it has received 510(k) clearance from ... its precision planning application for Transcatheter Aortic-Valve Implantation ... application provides interventionalists with pre-procedural, high-precision positioning to ... TAVI planning application is available as part of ...
(Date:8/20/2014)... 20, 2014 Northstar Global Business Services, ... months of hard work from many talented specialists, ... formulation and package design.  The new formulation for ... into the product due to overwhelming evidence of ... Snorenz Nighttime will also include these vitamins, as ...
Breaking Medicine Technology:AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2
... 25, 2007 /PRNewswire-FirstCall/ --,Genaera Corporation today announced ... (MSI-1436) for the treatment of obesity were,presented ... Sessions, June 22-25 in Chicago, IL. Dr. ... of Abstract #1801-P,presented, "Trodusquemine is a Multiple ...
... 25, 2007 - Gilead,Sciences, Inc. (Nasdaq:GILD) today ... trial evaluating the company's once-daily,anti-HIV drug Viread(R) ... as a potential treatment for chronic hepatitis ... endpoint. The data show,that Viread is non-inferior ...
Cached Medicine Technology:Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 2Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 3Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6
... Line ULTRA® Suctionaid® tracheostomy tubes provide an ... secretions from above the tracheostomy tube cuff. ... tracheostomy tubes provide an additional lumen to ... the tracheostomy tube cuff helping to reduce ...
Fenestrations allow your patients to vocalize when cuff is deflated...
The all silicone construction of the shaft and neck flange provides the utmost in patient comfort. , ,The Aire-Cuf® tracheostomy tube offers a more traditional and familiar air-filled cuff desig...
... Built-in 15 mm ISO termination for ... inner cannula in place. , ,Clearly ... inner cannula system , ,The Portex® ... constructed of siliconized polyvinyl chloride, providing a ...
Medicine Products: